NEXQ develops novel therapeutics for neurodegenerative diseases by targeting specific protein aggregates. Their platform utilizes advanced screening techniques to identify small molecules that inhibit aggregation and promote clearance, aiming to slow or halt disease progression.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for developing therapeutics for neurodegenerative diseases face challenges in effectively identifying and targeting specific protein aggregates responsible for disease progression. Traditional screening techniques may lack the precision needed to isolate small molecules that can both inhibit aggregation and promote the clearance of these harmful proteins.
Solution
NEXQ is developing a quantum-powered platform that leverages quantum computing and artificial intelligence to accelerate the discovery of novel therapeutics for neurodegenerative diseases. The platform employs advanced molecular modeling techniques, integrating quantum theory and computational simulations, to simulate molecular interactions at the quantum level. This allows for precise sectionalization and mapping of affected areas, such as brain tumors, and delivers optimal 3D drug delivery targets. By using Quantum Neural Networks (QNNs) and NIST-inspired quantum encryption algorithms, NEXQ enhances the accuracy and security of cancer diagnostics and treatment, ensuring hyper-personalized treatment plans and secure data handling.
Target Audience
NEXQ's primary target audience includes researchers, clinicians, and developers in the biotechnology and pharmaceutical industries focused on developing therapeutics for neurodegenerative diseases, oncology, and cardiovascular health.
Features
- Quantum Machine Learning (QML) for enhanced drug discovery
- Advanced molecular modeling (MM) techniques integrating quantum theory and computational simulations
- Quantum Neural Networks (QNNs) for medical image processing
- NIST-inspired quantum encryption algorithms for secure data handling
- TumorQ software for precise sectionalization and mapping of brain tumors, delivering optimal 3D drug delivery targets with 99.98% accuracy
- HeartQ software for cardiovascular health and longevity